Compounded versions of semaglutide, the active ingredient in approved diabetes ... Scott Brunner, CEO of the Alliance for ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

It also represents an escalation of efforts to crack down on clinics, compounding pharmacies and other manufacturers selling what it alleges are unsafe knockoff versions of semaglutide.

Demand for popular weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) has long outpaced supply, forcing many patients with obesity to visit compounding pharmacies to get ...

With the rising demand for weight-loss medications, compounding pharmacies have been making headlines lately. On October 30, ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Compounding pharmacies have increasingly been at the centre of safety concerns around the legitimacy and credibility of ...

The move is Novo Nordisk's latest attempt to crack down on potentially harmful copies of semaglutide after it filed 50 lawsuits against several clinics, compounding pharmacies and other ...

Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic.